CD19 and pancreatic neoplasm: Previous findings confirmed that patients with pancreatic cancer of IS2 and IS3 immune subtypes have a poor prognosis (Figures 7A,B), which led to the understanding that upregulated CD19 expression could potentially predict a poor prognosis in patients with pancreatic cancer.